Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FILANA THERAPEUTICS, INC.SAVA · Entity 7294 | Director | December 13, 2019 | December 16, 2019 |
| Faeth Therapeutics, Inc.FTH · Entity 5029 | Director | June 12, 2026 | June 16, 2026 |
| Mirum Pharmaceuticals, Inc.MIRM · Entity 2416 | Director | June 15, 2026 | June 18, 2026 |
| SANGAMO THERAPEUTICS, INCSGMO · Entity 7038 | Director | February 25, 2022 | March 01, 2022 |
| Vir Biotechnology, Inc.VIR · Entity 4522 | Director | May 30, 2025 | June 02, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FILANA THERAPEUTICS, INC.
Report date December 13, 2019 · Filed December 16, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.88 · Expires 2029-12-13 | Direct | 30,000 |
Reported balance
After 2019-12-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-12-13 · Grant · Acquired 30,000 · Balance 30,000 F1: Stock Options issued pursuant to the Company's Equity Incentive Plan vest over four (4) years at a rate of 1/48th each month. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock Options issued pursuant to the Company's Equity Incentive Plan vest over four (4) years at a rate of 1/48th each month.
Faeth Therapeutics, Inc.
Report date June 12, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.00 · Expires 2036-06-11 | Direct | 25,000 |
Reported balance
After 2026-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-12 · Grant · Acquired 25,000 · Balance 25,000 F1: The shares subject to the option vest and become exercisable in 36 equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, or June 12, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest and become exercisable in 36 equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, or June 12, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
Mirum Pharmaceuticals, Inc.
Report date June 15, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $101.00 · Expires 2036-06-14 | Direct | 3,772 |
Reported balance
After 2026-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 3,772 · Balance 3,772 F1: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,980 |
Reported balance
After 2026-06-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-15 · Grant · Acquired 1,980 · Balance 1,980 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting.
F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting.
SANGAMO THERAPEUTICS, INC
Report date February 25, 2022 · Filed March 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,700 |
Reported balance
After 2022-02-25 transaction · row 1
1 source rowRow 1 · 2022-02-25 · Grant · Acquired 12,500 · Balance 35,700 F1: Represents shares of common stock issuable upon settlement of a restricted stock unit grant that will fully vest on the first anniversary of the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.90 · Expires 2032-02-24 | Direct | 25,000 |
Reported balance
After 2022-02-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-02-25 · Grant · Acquired 25,000 · Balance 25,000 F2: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock issuable upon settlement of a restricted stock unit grant that will fully vest on the first anniversary of the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP.
F2: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
Vir Biotechnology, Inc.
Report date May 30, 2025 · Filed June 02, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,619 |
Reported balance
After 2025-05-30 transaction · row 1
1 source rowRow 1 · 2025-05-30 · Grant · Acquired 8,000 · Balance 22,619 F1: Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan. F2: The RSUs will vest in full on May 30, 2026. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.94 · Expires 2035-05-29 | Direct | 16,000 |
Reported balance
After 2025-05-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-05-30 · Grant · Acquired 16,000 · Balance 16,000 F3: The shares subject to the stock option will vest and become exercisable in full on May 30, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.
F2: The RSUs will vest in full on May 30, 2026.
F3: The shares subject to the stock option will vest and become exercisable in full on May 30, 2026.
Past disclosures · reporting ended (4)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
9 METERS BIOPHARMA, INC.
Report date April 24, 2020 · Filed May 04, 2020
Section 16 reporting ended · disclosed 2020-05-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.60 · Expires 2030-04-24 | Direct | 25,000 |
Reported balance
After 2020-04-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-04-24 · Grant · Acquired 25,000 · Balance 25,000 F1: This option vested in full on the grant date, 4/24/2020. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vested in full on the grant date, 4/24/2020.
Akouos, Inc.
Report date December 01, 2022 · Filed December 02, 2022
Section 16 reporting ended · disclosed 2022-12-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.21 · Expires 2032-06-22 | Direct | 0 |
Reported balance
After 2022-12-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-12-01 · Disposition to issuer · Disposed 16,000 · Balance 0 F1: At the effective time of the merger (the "Effective Time"), pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Kearny Acquisition Corporation ("Merger Sub"), dated as of October 17, 2022, each outstanding option to purchase shares of common stock, par value $0.0001 per share, of the Issuer ("Shares") having an exercise price less than $12.50 per Share, whether or not vested, was cancelled and converted into the right to receive (x) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (A) the total number of Shares subject to such option immediately prior to the Effective Time multiplied by [Continued on Note 2] F2: [Continuation of Note 1] (B) the excess, if any, of $12.50 per Share over the applicable exercise price per Share under such option and (y) one nontradable contingent value right ("CVR") for each Share subject to such option immediately prior to the Effective Time (without regard to vesting), which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of November 30, 2022, by and among Parent, Merger Sub, Computershare Inc. and Computershare Trust Company, N.A. |
Filing footnotes · ownership attribution and instrument terms
F1: At the effective time of the merger (the "Effective Time"), pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Kearny Acquisition Corporation ("Merger Sub"), dated as of October 17, 2022, each outstanding option to purchase shares of common stock, par value $0.0001 per share, of the Issuer ("Shares") having an exercise price less than $12.50 per Share, whether or not vested, was cancelled and converted into the right to receive (x) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (A) the total number of Shares subject to such option immediately prior to the Effective Time multiplied by [Continued on Note 2]
F2: [Continuation of Note 1] (B) the excess, if any, of $12.50 per Share over the applicable exercise price per Share under such option and (y) one nontradable contingent value right ("CVR") for each Share subject to such option immediately prior to the Effective Time (without regard to vesting), which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of November 30, 2022, by and among Parent, Merger Sub, Computershare Inc. and Computershare Trust Company, N.A.
Day One Biopharmaceuticals, Inc.
Report date April 23, 2026 · Filed April 23, 2026
Section 16 reporting ended · disclosed 2026-04-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 1
1 source rowRow 1 · 2026-04-23 · Disposition to issuer · Disposed 40,485 · Balance 0 F1: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement. |
| Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2031-05-25 | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-23 · Disposition to issuer · Disposed 40,000 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F3: The options are fully vested. |
| Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2031-05-25 | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-23 · Disposition to issuer · Disposed 47,581 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F3: The options are fully vested. |
| Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2032-06-20 | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-23 · Disposition to issuer · Disposed 28,700 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F3: The options are fully vested. |
| Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2033-06-21 | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-04-23 · Disposition to issuer · Disposed 37,500 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F3: The options are fully vested. |
| Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2034-05-22 | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-04-23 · Disposition to issuer · Disposed 32,335 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F3: The options are fully vested. |
| Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $7.01 · Expires 2035-06-01 | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-04-23 · Disposition to issuer · Disposed 22,500 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F5: The option vests as to 1/12th of the total grant on each monthly anniversary, beginning on July 2, 2025, subject to the Reporting Person's provision of service to the Issuer on each option vesting date. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-04-23 · Disposition to issuer · Disposed 15,000 · Balance 0 F6: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F7: The RSUs will vest as to 100% of the award on the earlier of (i) June 2, 2026 and (ii) the date of the Issuer's 2026 annual meeting of stockholders (in each case, the "RSU Vesting Date"), subject to the Reporting Person's provision of services to the Issuer on each vesting date. On the RSU Vesting Date, pursuant to the Reporting Person's election, the RSUs will automatically convert into an equal number of deferred stock units, which will be settled for an equal number of shares of the Issuer's Common Stock on the earlier of the calendar year 2030 or the Reporting Person's separation with the Issuer. Notwithstanding the aforementioned deferral period, from and after the RSU Vesting Date, the deferred stock units may settle earlier upon the Reporting Person's death, disability, or separation from service with the Issuer, or upon the occurrence of an "unforeseeable emergency," as that term is defined under the Issuer's deferred compensation plan. F8: RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent.
F2: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement.
F3: The options are fully vested.
F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes.
F5: The option vests as to 1/12th of the total grant on each monthly anniversary, beginning on July 2, 2025, subject to the Reporting Person's provision of service to the Issuer on each option vesting date.
F6: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
F7: The RSUs will vest as to 100% of the award on the earlier of (i) June 2, 2026 and (ii) the date of the Issuer's 2026 annual meeting of stockholders (in each case, the "RSU Vesting Date"), subject to the Reporting Person's provision of services to the Issuer on each vesting date. On the RSU Vesting Date, pursuant to the Reporting Person's election, the RSUs will automatically convert into an equal number of deferred stock units, which will be settled for an equal number of shares of the Issuer's Common Stock on the earlier of the calendar year 2030 or the Reporting Person's separation with the Issuer. Notwithstanding the aforementioned deferral period, from and after the RSU Vesting Date, the deferred stock units may settle earlier upon the Reporting Person's death, disability, or separation from service with the Issuer, or upon the occurrence of an "unforeseeable emergency," as that term is defined under the Issuer's deferred compensation plan.
F8: RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date.
REPROS THERAPEUTICS INC.
Report date January 29, 2018 · Filed January 31, 2018
Section 16 reporting ended · disclosed 2018-01-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2018-01-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-01-29 · Other · Disposed 12,221 · Balance 27,779 Row 2 · 2018-01-31 · Disposition to issuer · Disposed 27,779 · Balance 0 F1: Consists of restricted stock units. Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated December 11, 2018, by and among Repros Therapeutics Inc. (the "Issuer"), Allergan Sales, LLC ("Parent") and Celestial Merger Sub, Inc. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each outstanding restricted stock unit and any associated rights to the issuance of shares of the Issuer's common stock, par value $0.001 per share (the "Shares") upon the achievement of Issuer performance goals (the "Issuer RSUs") under the Issuer's equity plans that was not then vested was cancelled, (continued in Footnote 2) F2: (continued from Footnote 1) and the holder of such cancelled Issuer RSUs became entitled to receive, in exchange therefor, an amount in cash equal to the product of (x) the total number of Shares subject to (or deliverable under) such Issuer RSUs immediately prior to the effective time of the Merger (the "Effective Time") (determined after giving effect to the accelerated vesting and deemed achievement at maximum applicable performance levels) multiplied by (y) $0.67 in cash (the "Closing Amount"). These restricted stock units were fully vested immediately prior to the Effective Time. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.32 · Expires 2027-09-15 | Direct | 0 |
Reported balance
After 2018-01-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-01-31 · Disposition to issuer · Disposed 5,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each option to purchase Shares (a "Company Option") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than the Closing Amount (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled at the Effective Time without any consideration payable therefor. F4: The Shares subject to this option were fully vested immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of restricted stock units. Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated December 11, 2018, by and among Repros Therapeutics Inc. (the "Issuer"), Allergan Sales, LLC ("Parent") and Celestial Merger Sub, Inc. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each outstanding restricted stock unit and any associated rights to the issuance of shares of the Issuer's common stock, par value $0.001 per share (the "Shares") upon the achievement of Issuer performance goals (the "Issuer RSUs") under the Issuer's equity plans that was not then vested was cancelled, (continued in Footnote 2)
F2: (continued from Footnote 1) and the holder of such cancelled Issuer RSUs became entitled to receive, in exchange therefor, an amount in cash equal to the product of (x) the total number of Shares subject to (or deliverable under) such Issuer RSUs immediately prior to the effective time of the Merger (the "Effective Time") (determined after giving effect to the accelerated vesting and deemed achievement at maximum applicable performance levels) multiplied by (y) $0.67 in cash (the "Closing Amount"). These restricted stock units were fully vested immediately prior to the Effective Time.
F3: Pursuant to the terms of the Merger Agreement, each option to purchase Shares (a "Company Option") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than the Closing Amount (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled at the Effective Time without any consideration payable therefor.
F4: The Shares subject to this option were fully vested immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2020 Filed May 26, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 28,888 | $0.00 Strike: $37.06 | $0.00 |
DisclosureSEC source: 0001209191-20-032062 · doc4.xml · derivative · entry 1 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,888 Underlying: Common Stock · 28,888 shares Expires 2030-05-21 Read SEC document |
| May 21, 2020 Filed Oct 13, 2020 23:13 UTC Amendment | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 24,497 | $0.00 Strike: $37.06 | $0.00 |
DisclosureSEC source: 0001209191-20-054740 · doc4a.xml · derivative · entry 1 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,497 Underlying: Common Stock · 24,497 shares Expires 2030-05-20 Read SEC document |
| May 18, 2020 Filed May 20, 2020 21:19 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $10.46 | $0.00 |
DisclosureSEC source: 0001209191-20-030961 · doc4.xml · derivative · entry 2 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-05-17 F2 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's service on the Board of the Directors of the Issuer. The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Board service over the 12-month period measured from the grant date. Read SEC document |
| May 18, 2020 Filed May 20, 2020 21:19 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-030961 · doc4.xml · nonDerivative · entry 1 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) May 18, 2021 (the first anniversary of the date of grant) or (y) the day prior to the 2021 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| May 18, 2020 Filed Jun 3, 2020 20:29 UTC Amendment | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $10.46 | $0.00 |
DisclosureSEC source: 0001209191-20-034026 · doc4a.xml · derivative · entry 2 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-05-17 F3 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP, as amended). The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Continuous Service (as defined in the 2018 EIP, as amended) over the 12-month period measured from the grant date and subject to acceleration as provided in the 2018 EIP, as amended. Read SEC document |
| May 18, 2020 Filed Jun 3, 2020 20:29 UTC Amendment | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-034026 · doc4a.xml · nonDerivative · entry 1 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) May 18, 2021 (the first anniversary of the date of grant) or (y) the day prior to the 2021 annual stockholders meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended")), through such date and subject to acceleration as provided in the 2018 EIP, as amended. F2 · shares: This Form 4/A is being filed solely to correct the stated grant amounts which were erroneously reported on Form 4 filed on behalf of the Reporting Person on May 20, 2020. Pursuant to the 2018 EIP, as amended, and the Automatic Grant Program for Non-Employee Directors thereunder, the annual grant amounts increased effective with the approval of the 2018 EIP, as amended, by the stockholders of the Issuer on May 18, 2020. Such previously filed Form 4 incorrectly stated grant amounts pursuant to the Automatic Grant Program for Non-Employee Directors prior to such amendment and restatement of the 2018 Equity Incentive Plan. Read SEC document |
| April 24, 2020 Filed May 4, 2020 21:54 UTC | 9 METERS BIOPHARMA, INC. NMTR · Entity 114271 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001551986-20-000105 · wf-form4_158862923482503.xml · derivative · entry 1 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common stock · 25,000 shares Expires 2030-04-24 F1 · derivative.exercise_date: This option vested in full on the grant date, 4/24/2020. Read SEC document |
| December 13, 2019 Filed Dec 16, 2019 21:00 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.88 | $0.00 |
DisclosureSEC source: 0001069530-19-000053 · certent-form4.xml · derivative · entry 1 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-12-13 F1 · derivative.exercise_date: Stock Options issued pursuant to the Company's Equity Incentive Plan vest over four (4) years at a rate of 1/48th each month. Read SEC document |
| December 10, 2019 Filed Dec 12, 2019 21:20 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 57,777 | $0.00 Strike: $12.76 | $0.00 |
DisclosureSEC source: 0001209191-19-060214 · doc4.xml · derivative · entry 1 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,777 Underlying: Common Stock · 57,777 shares Expires 2029-12-10 F1 · derivative.exercise_date: 1/3 of the shares subject to the stock option vest and become exercisable on September 4, 2020, and the remaining shares vest in 24 equal monthly installments thereafter. Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 21:08 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $9.38 | $0.00 |
DisclosureSEC source: 0001209191-19-036442 · doc4.xml · derivative · entry 2 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-06-09 F2 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's service on the Board of the Directors of the Issuer. The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Board service over the 12-month period measured from the grant date. Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 21:08 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-036442 · doc4.xml · nonDerivative · entry 1 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) June 10, 2020 (the first anniversary of the date of grant) or (y) the day prior to the 2020 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| May 31, 2019 Filed Jun 4, 2019 21:31 UTC | 9 METERS BIOPHARMA, INC. INNT · Entity 114271 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0001551986-19-000065 · wf-form4_155968386513802.xml · derivative · entry 1 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common stock · 25,000 shares Expires 2029-05-31 F1 · derivative.exercise_date: Grant to the reporting person of stock options under the Innovate Biopharmaceuticals, Inc. 2012 Omnibus Incentive Plan. These stock options vest in 36 equal monthly installments. Read SEC document |
| December 04, 2018 Filed Dec 7, 2018 22:21 UTC | 9 METERS BIOPHARMA, INC. INNT · Entity 114271 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.41 | $0.00 |
DisclosureSEC source: 0001551986-18-000067 · wf-form4_154422126504841.xml · derivative · entry 2 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common stock · 25,000 shares Expires 2028-12-04 F2 · derivative.exercise_date: Grant to the reporting person of stock options under the Innovate Biopharmaceuticals, Inc. 2012 Omnibus Incentive Plan. These stock options vest in 36 equal monthly installments. Read SEC document |
| December 04, 2018 Filed Dec 7, 2018 22:21 UTC | 9 METERS BIOPHARMA, INC. INNT · Entity 114271 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $6.94 | $0.00 |
DisclosureSEC source: 0001551986-18-000067 · wf-form4_154422126504841.xml · derivative · entry 1 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common stock · 50,000 shares Expires 2028-09-21 F1 · date: Grant to the reporting person of stock options under the Innovate Biopharmaceuticals, Inc. 2012 Omnibus Incentive Plan (the "Plan") that was approved by the Compensation Committee of the Board of Directors of Innovate Biopharmaceuticals, Inc. (the "Company") on September 21, 2018, subject to stockholder approval of an amendment to the Plan (the "Plan Amendment"). The Company's stockholders approved the Plan Amendment on December 4, 2018. 13,750 of these options vested on September 21, 2018, and 36,250 options vest monthly thereafter over 29 months. F1 · derivative.exercise_date: Grant to the reporting person of stock options under the Innovate Biopharmaceuticals, Inc. 2012 Omnibus Incentive Plan (the "Plan") that was approved by the Compensation Committee of the Board of Directors of Innovate Biopharmaceuticals, Inc. (the "Company") on September 21, 2018, subject to stockholder approval of an amendment to the Plan (the "Plan Amendment"). The Company's stockholders approved the Plan Amendment on December 4, 2018. 13,750 of these options vested on September 21, 2018, and 36,250 options vest monthly thereafter over 29 months. Read SEC document |
| September 14, 2018 Filed Sep 18, 2018 23:08 UTC | FILANA THERAPEUTICS, INC. PTIE · Entity 7294 | GrantStock Options(1) · Derivative | 15,000 | $0.95 Strike: $0.95 | $14,250.00 |
DisclosureSEC source: 0001069530-18-000049 · primary_doc.xml · derivative · entry 1 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,991 Underlying: Common Stock · 15,000 shares Expires 2028-09-14 Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 00:28 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $15.65 | $0.00 |
DisclosureSEC source: 0001209191-18-037349 · doc4.xml · derivative · entry 2 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-10 F2 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's service on the Board of the Directors of the Issuer. The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Board service over the 12-month period measured from the grant date. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 00:28 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-037349 · doc4.xml · nonDerivative · entry 1 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) June 11, 2019 (the first anniversary of the date of grant) or (y) the day prior to the 2019 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| February 26, 2018 Filed Feb 27, 2018 23:41 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,450 | $0.00 Strike: $5.03 | $0.00 |
DisclosureSEC source: 0001209191-18-014220 · doc4.xml · derivative · entry 3 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,450 shares Expires 2022-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Option is fully vested and exercisable. Read SEC document |
| February 26, 2018 Filed Feb 27, 2018 23:41 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | SaleCommon Stock | 9,450 | $24.88 | $235,080.09 |
DisclosureSEC source: 0001209191-18-014220 · doc4.xml · nonDerivative · entry 2 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported is a weighted average price. The shares were sold at prices ranging from $24.85 to $24.905 The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 26, 2018 Filed Feb 27, 2018 23:41 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionCommon Stock | 9,450 | $5.03 | $47,533.50 |
DisclosureSEC source: 0001209191-18-014220 · doc4.xml · nonDerivative · entry 1 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,450 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2018 Filed Jan 31, 2018 10:01 UTC | REPROS THERAPEUTICS INC. RPRX · Entity 169957 | Disposition to issuerStock Option · Derivative | 5,000 | Not disclosed Strike: $0.32 | Not disclosed |
DisclosureSEC source: 0001144204-18-004784 · tv484343_4.xml · derivative · entry 3 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2027-09-15 F3 · price: Pursuant to the terms of the Merger Agreement, each option to purchase Shares (a "Company Option") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than the Closing Amount (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled at the Effective Time without any consideration payable therefor. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option to purchase Shares (a "Company Option") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than the Closing Amount (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled at the Effective Time without any consideration payable therefor. F4 · derivative.exercise_date: The Shares subject to this option were fully vested immediately prior to the Effective Time. Read SEC document |
| January 31, 2018 Filed Jan 31, 2018 10:01 UTC | REPROS THERAPEUTICS INC. RPRX · Entity 169957 | Disposition to issuerCommon Stock | 27,779 | $0.67 | $18,611.93 |
DisclosureSEC source: 0001144204-18-004784 · tv484343_4.xml · nonDerivative · entry 2 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Consists of restricted stock units. Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated December 11, 2018, by and among Repros Therapeutics Inc. (the "Issuer"), Allergan Sales, LLC ("Parent") and Celestial Merger Sub, Inc. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each outstanding restricted stock unit and any associated rights to the issuance of shares of the Issuer's common stock, par value $0.001 per share (the "Shares") upon the achievement of Issuer performance goals (the "Issuer RSUs") under the Issuer's equity plans that was not then vested was cancelled, (continued in Footnote 2) F2 · price: (continued from Footnote 1) and the holder of such cancelled Issuer RSUs became entitled to receive, in exchange therefor, an amount in cash equal to the product of (x) the total number of Shares subject to (or deliverable under) such Issuer RSUs immediately prior to the effective time of the Merger (the "Effective Time") (determined after giving effect to the accelerated vesting and deemed achievement at maximum applicable performance levels) multiplied by (y) $0.67 in cash (the "Closing Amount"). These restricted stock units were fully vested immediately prior to the Effective Time. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 10:01 UTC | REPROS THERAPEUTICS INC. RPRX · Entity 169957 | OtherCommon Stock | 12,221 | $0.67 | $8,188.07 |
DisclosureSEC source: 0001144204-18-004784 · tv484343_4.xml · nonDerivative · entry 1 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,779 Read SEC document |
| December 06, 2017 Filed Dec 8, 2017 22:16 UTC | FILANA THERAPEUTICS, INC. PTIE · Entity 7294 | GrantNon-Qualifying Stock Options (1) · Derivative | 22,500 | $4.09 Strike: $4.09 | $92,025.00 |
DisclosureSEC source: 0001069530-17-000042 · primary_doc.xml · derivative · entry 1 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,991 Underlying: Common Stock · 22,500 shares Expires 2027-12-06 Read SEC document |
| November 17, 2017 Filed Nov 21, 2017 22:01 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $5.03 | $0.00 |
DisclosureSEC source: 0001209191-17-062112 · doc4.xml · derivative · entry 3 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,450 Underlying: Common Stock · 5,000 shares Expires 2022-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Option is fully vested and exercisable. Read SEC document |
| November 17, 2017 Filed Nov 21, 2017 22:01 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | SaleCommon Stock | 5,000 | $14.67 | $73,339.00 |
DisclosureSEC source: 0001209191-17-062112 · doc4.xml · nonDerivative · entry 2 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| November 17, 2017 Filed Nov 21, 2017 22:01 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionCommon Stock | 5,000 | $5.03 | $25,150.00 |
DisclosureSEC source: 0001209191-17-062112 · doc4.xml · nonDerivative · entry 1 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2017 Filed Sep 18, 2017 16:03 UTC | REPROS THERAPEUTICS INC. RPRX · Entity 169957 | GrantStock Option · Derivative | 5,000 | Not disclosed Strike: $0.32 | Not disclosed |
DisclosureSEC source: 0001144204-17-048491 · v475368_4.xml · derivative · entry 1 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common · 5,000 shares Expires 2027-09-15 F2 · price: Received as compensation for service on Board of Directors of issuer. F1 · derivative.exercise_date: Option shares shall vest in equal monthly installments over the first twelve months after the date of grant. Read SEC document |
| June 16, 2017 Filed Jun 19, 2017 21:27 UTC | FILANA THERAPEUTICS, INC. PTIE · Entity 7294 | GrantNon-Qualifying Stock Options (1) · Derivative | 2,500 | $4.10 Strike: $4.10 | $10,250.00 |
DisclosureSEC source: 0001573723-17-000007 · primary_doc.xml · derivative · entry 1 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,500 Underlying: Common Stock · 2,500 shares Expires 2027-06-16 Read SEC document |
| June 05, 2017 Filed Jun 7, 2017 22:03 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001140361-17-024395 · doc1.xml · derivative · entry 1 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-06-04 F1 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon the cessation of the Reporting Person's service on the Board of Directors of the Issuer. The shares subject to each option vest in monthly installments upon completion of each month of Board service over a one year period. Read SEC document |
| May 04, 2017 Filed May 5, 2017 20:36 UTC | FILANA THERAPEUTICS, INC. PTIE · Entity 7294 | GrantNon-Qualifying Stock Options (1) · Derivative | 50,000 | $0.78 Strike: $0.78 | $39,000.00 |
DisclosureSEC source: 0001573723-17-000001 · primary_doc.xml · derivative · entry 1 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 385,000 Underlying: Common Stock · 50,000 shares Expires 2027-05-04 Read SEC document |
| February 13, 2017 Filed Feb 15, 2017 16:32 UTC | REPROS THERAPEUTICS INC. RPRX · Entity 169957 | GrantCommon Stock | 40,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001144204-17-009373 · v459725_4.xml · nonDerivative · entry 1 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 F1 · price: Consists of Restricted Stock Units (RSUs), representing the right to receive one share of the issuer's common stock for each vested RSU, that were awarded on February 13, 2017 as compensation to non-employee members of the Board of Directors. The RSUs shall vest in thirty-six (36) equal increments on the last day of each calendar month from February 2017 through January 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.